Do most people experience side effects from Wegovy?

What the STEP 1 trial actually found

The STEP 1 study (a 68-week randomised controlled trial published in the New England Journal of Medicine) remains the most cited evidence base for semaglutide 2.4mg in weight management. Of the adults receiving the active treatment, roughly 74% reported a gastrointestinal adverse event, compared with around 48% on placebo. That gap is meaningful: the medicine is clearly the driver of most GI symptoms, not background noise. Nausea was the single most common complaint, followed by diarrhoea, vomiting and constipation. Serious adverse events leading to treatment discontinuation occurred in a smaller proportion, just under 7% in the active arm.

Those numbers sound high until you look at the severity breakdown. The overwhelming majority of reported events were rated mild or moderate. Rates of any given symptom also dropped considerably after the initial titration period. The dose escalation schedule (moving through 0.25mg, 0.5mg, 1.0mg, 1.7mg and eventually 2.4mg, each step roughly four weeks apart) is designed partly for this reason: gradual increases give the body time to adapt. Some people find the step-up weeks harder than the steady weeks in between.

For a fuller breakdown of exactly how common individual effects were, including what percentage of people have side effects from Wegovy, the per-symptom frequency data is worth reading before you start treatment.

When side effects are most likely to hit, and when they tend to ease

Timing matters here more than people expect. Nausea and loose stools typically peak in the first one to two weeks after starting or after a dose increase, then gradually settle as the body acclimatises. Many people who push through the first fortnight at a new dose find the weeks that follow are noticeably more comfortable. This pattern is consistent enough that it shapes how prescribers advise patients to plan their early weeks, if you are starting treatment just before a busy period, say a work trip or a run of social commitments, mentioning that to your prescriber during your consultation is worth doing.

That said, not everyone follows the same arc. A minority of people find nausea persists, and for some it becomes a reason to pause or reconsider dose escalation. Slower titration is an option your prescriber can discuss. The NHS medicines information for semaglutide sets out the common side effects along with practical advice on managing them, and is a reliable first reference. Some effects (like sulphurous burping) are less discussed but genuinely common; our page on Wegovy and digestive gas covers that specifically.

Fatigue, headache and dizziness appear in the trial data too, though less frequently than the GI effects. Injection-site reactions (redness, bruising, itching at the pen site) are also reported and are usually short-lived.

When to get medical help, side effects that need urgent attention

Most people on Wegovy will not experience anything beyond the GI effects described above. But a small number of serious reactions have been identified, and it is important to know which symptoms should prompt you to seek help promptly rather than wait and see.

Pancreatitis is the one that clinicians are most vigilant about. On 29 January 2026 the MHRA issued a Drug Safety Update for GLP-1 receptor agonist medicines confirming that acute pancreatitis, whilst infrequent, is a recognised risk. The symptom to act on is severe, persistent abdominal pain, especially pain that spreads through to the back, with or without vomiting. This needs same-day medical assessment; do not manage it at home.

Other symptoms that warrant prompt contact with a clinician or 999 in an emergency: signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, a rapidly spreading rash), severe vomiting or diarrhoea leading to signs of dehydration, and significant changes in mood or thoughts of self-harm. The full guide to Wegovy side effects covers these categories in more detail, including what to tell a GP or A&E team if you need to present.

You can report any suspected side effect (including effects not listed in the Patient Information Leaflet) through the MHRA's Yellow Card scheme. Reports from real-world users are how regulators detect signals that trials miss.

Does everyone get side effects, or can you avoid them entirely?

No, not everyone experiences noticeable side effects, and the trial data backs that up. Roughly a quarter of STEP 1 participants on active treatment reported no gastrointestinal adverse event at all. Individual variation is real. Factors like how strictly the injection timing and eating patterns are managed, how hydrated someone stays, and individual gut sensitivity all play a role in how the medicine lands. Our page on people who tolerate Wegovy well looks at this more closely, including what habits seem to make the early weeks easier.

A prescriber's job is to weigh your specific history (other medicines you take, any relevant conditions, your previous experience with GLP-1 treatments if you have transferred from elsewhere) against the known side-effect profile before recommending Wegovy. That is what the consultation at our prescribing service is for: a clinician reviews whether the medicine is appropriate for you and talks through what to expect. It is not a formality; it is the process that makes this a safe prescription rather than a gamble.